Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Purpose: In recent retrospective analyses of early-stage colorectal cancer (CRC), low and high body mass index (BMI) scores were associated with worsened outcomes. Whether BMI is a prognostic or predictive factor in metastatic CRC (mCRC) is unclear. Patients and Methods: Individual data from 21,149 patients enrolled onto 25 first-line mCRC trials during 1997 to 2012 were pooled. We assessed both prognostic and predictive effects of BMI on overall survival and progression-free survival, and we accounted for patient and tumor characteristics and therapy type (targeted v nontargeted). Results: BMI was prognostic for overall survival (P < .001) and progression-free survival (P < .001), with an L-shaped pattern. That is, risk of progression and/or death was greatest for low BMI; risk decreased as BMI increased to approximately 28 kg/m 2, and then it plateaued. Relative to obese patients, patients with a BMI of 18.5 kg/m 2 had a 27% increased risk of having a PFS event (95% CI, 20% to 34%) and a 50% increased risk of death (95% CI, 43% to 56%). Low BMI was associated with poorer survival for men than women (interaction P < .001). BMI was not predictive of treatment effect. Conclusion: Low BMI is associated with an increased risk of progression and death among the patients enrolled on the mCRC trials, with no increased risk for elevated BMI, in contrast to the adjuvant setting. Possible explanations include negative effects related to cancer cachexia in patients with low BMI, increased drug delivery or selection bias in patients with high BMI, and potential for an interaction between BMI and molecular signaling pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Harrell, F. E. (2001) · Springer Series in Statistics · doi:10.1007/978-1-4757-3462-1 · Cited by 9,195
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885 · cited 2×
“For each variable included in prognostic and predictive analyses, the assumption of proportional hazards was assessed by using the method of Therneau and Grambsch.14 When the proportional hazards assumption was violated, as indicated by both P , .01 and visually apparent nonproportionality (ie, of Kaplan-Meier surviva…”
MethodMartin, L., Birdsell, L., MacDonald, N., Reiman, T., Clandinin, M. T., McCargar, L. J., Murphy, R., Ghosh, S., Sawyer, M. B., & Baracos, V. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2722 · Cited by 2,680 · cited 4×
“Furthermore, cachexia and associated weight loss have previously been identified as negative prognostic factors in patients with CRC.(20,21) In 2009, Lieffers et al(22) hypothesized that a viscerally driven cachexia syndrome in patients with CRC originates from an increase in mass of high-metabolic-rate tissues, such…”
BackgroundInfluentialCancer cachexia: understanding the molecular basis
Argilés, J. M., Busquets, S., Stemmler, B., & López-Soriano, F. J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3829 · Cited by 1,517 · cited 1×
“Cancer cachexia affects approximately 50% of patients with colon cancer, and across all tumor groups, cachexia is associated with a 20% mortality rate.(18) Patients with tumors in the GI tract generally experience a large degree of weight loss, which in turn is associated with shorter survival times, worsened PS, and…”
BackgroundTisdale, M. J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc927 · Cited by 982
Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies
Larsson, S. C., & Wolk, A. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.556 · Cited by 632
Sandhu, M. S. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.13.972 · Cited by 496 · cited 1×
“For example, insulin resistance, hyperinsulinemia, increased levels of insulin-like growth factor, elevated levels of steroid and peptide hormones, and inflammatory markers appear to play a role in the connection between obesity and outcome in patients with cancer.(8) Here, we examine whether patient BMI is prognostic…”
BackgroundMultiple Imputation for Nonresponse in Surveys.
Kershaw, C. D., & Rubin, D. B. (1989) · Biometrics · doi:10.2307/2532070 · Cited by 388
Body Mass Index and Outcomes in Patients Who Receive Adjuvant Chemotherapy for Colon Cancer
Dignam, J. J., Polite, B. N., Yothers, G., Raich, P., Colangelo, L., O'Connell, M. J., & Wolmark, N. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj442 · Cited by 325
Meyerhardt, J. A., Niedzwiecki, D., Hollis, D., Saltz, L. B., Mayer, R. J., Nelson, H., Whittom, R., Hantel, A., Thomas, J., & Fuchs, C. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6687 · Cited by 259
Self-citationLieffers, J. R., Mourtzakis, M., Hall, K. D., McCargar, L. J., Prado, C. M., & Baracos, V. E. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.27273 · Cited by 251
Molecular Pathways: Estrogen Pathway in Colorectal Cancer
Barzi, A., Lenz, A. M., Labonte, M. J., & Lenz, H.-J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0325 · Cited by 239
Self-citationFlegal, K. M., Graubard, B. I., Williamson, D. F., & Cooper, R. S. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwq341 · Cited by 223 · cited 1×
“Similarly, other authors have proposed that preexisting illness could result in unintended weight loss and higher mortality in patients with lower BMI as a possible methodologic explanation for the association between higher BMI and better outcome.(23,24) It is also plausible that some patients with low BMI and poor P…”
BackgroundGender Disparities in Metastatic Colorectal Cancer Survival
Hendifar, A., Yang, D., Lenz, F., Lurje, G., Pohl, A., Lenz, C., Ning, Y., Zhang, W., & Lenz, H.-J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0877 · Cited by 206
Self-citationObesity Is an Independent Prognostic Variable in Colon Cancer Survivors
Sinicrope, F. A., Foster, N. R., Sargent, D. J., O'Connell, M. J., & Rankin, C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2636 · Cited by 202
Self-citationThoresen, L., Frykholm, G., Lydersen, S., Ulveland, H., Baracos, V., Prado, C. M. M., Birdsell, L., & Falkmer, U. (2013) · Clinical Nutrition · doi:10.1016/j.clnu.2012.05.009 · Cited by 185 · cited 4×
“Furthermore, cachexia and associated weight loss have previously been identified as negative prognostic factors in patients with CRC.(20,21) In 2009, Lieffers et al(22) hypothesized that a viscerally driven cachexia syndrome in patients with CRC originates from an increase in mass of high-metabolic-rate tissues, such…”
BackgroundInfluentialSinicrope, F. A., Foster, N. R., Yothers, G., Benson, A., Seitz, J. F., Labianca, R., Goldberg, R. M., DeGramont, A., O'Connell, M. J., Sargent, D. J., et al. (2013) · Cancer · doi:10.1002/cncr.27938 · Cited by 179
Self-citationLieu, C. H., Renfro, L. A., de Gramont, A., Meyers, J. P., Maughan, T., Seymour, M., Saltz, L. B., Goldberg, R. M., Sargent, D. J., Eckhardt, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.9329 · Cited by 167 · cited 1×
“Since its inception, the ARCAD database has been used to evaluate progression-free survival (PFS) as a surrogate end point for OS(10) and to demonstrate that patient age is a strong prognostic factor for OS and PFS; young patients have the highest risk.(11) In the present analysis, patients from first-line trials incl…”
MethodSelf-citationReverse Causality and Confounding and the Associations of Overweight and Obesity with Mortality
Lawlor, D. A., Hart, C. L., Hole, D. J., & Smith, G. D. (2006) · Obesity · doi:10.1038/oby.2006.269 · Cited by 148
Shi, Q., de Gramont, A., Grothey, A., Zalcberg, J. R., Chibaudel, B., Schmoll, H., Seymour, M., Adams, R., Saltz, L. B., Goldberg, R. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.5887 · Cited by 110
Self-citationSimkens, L. H. J., Koopman, M., Mol, L., Veldhuis, G. J., Huinink, D. T. B., Muller, E. W., Derleyn, V. A., Teerenstra, S., & Punt, C. J. A. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.038 · Cited by 101 · cited 2×
“Simkens et al(7) analyzed data from patients in the clinical trials CAIRO (capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer) for chemotherapy and CAIRO2 for chemotherapy plus targeted (T) therapy to look for an association between BMI and OS.(7) Among the 796 patients on the CAIRO study, a highe…”
MethodSelf-citationToward Efficient Trials in Colorectal Cancer: The ARCAD Clinical Trials Program
de Gramont, A., Haller, D. G., Sargent, D. J., Tabernero, J. M., Matheson, A. I., & Schilsky, R. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.2544 · Cited by 28 · cited 1×
“Database The database created by the ARCAD Foundation contains patient-level data frommore than 33,000 individuals enrolled on 39 international first-line and subsequent-line clinical trials for mCRC conducted from 1997 to the present.(9) The focus of ARCAD is integration of high-quality data across similar trials wit…”
MethodSelf-citation
Cited by
From tumour heterogeneity to advances in precision treatment of colorectal cancer
Punt, C. J. A., Koopman, M., & Vermeulen, L. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.171 · Cited by 654
Self-citation
Metadata
- Authors
- Renfro, L. A., Loupakis, F., Adams, R. A., Seymour, M. T., Heinemann, V., Schmoll, H.-J., Douillard, J.-Y., Hurwitz, H., Fuchs, C. S., Diaz-Rubio, E., Porschen, R., Tournigand, C., Chibaudel, B., Falcone, A., Tebbutt, N. C., Punt, C. J. A., Hecht, J. R., Bokemeyer, C., Van Cutsem, E., Goldberg, R. M., Saltz, L. B., de Gramont, A., Sargent, D. J., & Lenz, H.-J.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-01-10
- Volume
- 34
- Issue
- 2
- Pages
- 144-150
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1824621050
- Cited by
- 162
- References
- 23
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.